Is superior the creatinine level regarding to the presence of albuminuria in their association with cardiovascular events in patients with type 2 diabetes mellitus?
DOI:
https://doi.org/10.47196/diab.v58i1.750Keywords:
type 2 diabetes mellitus, creatinine, albuminuria, cardiovascular adverse eventsAbstract
Introduction: the cardiovascular disease and the kidney disease constitute the main cause of mortality in type 2 diabetics patients so it matters to know the relative value of the creatinine level and the presence of albuminuria in the prediction of cardiovascular events (CVE) in them.
Objetives: to know the strength of association between creatinine levels and the presence of albuminuria with CVE in type 2 diabetics patients.
Materials and methods: in 270 type 2 diabetic patients (138 men and 132 women), age X 66±10,2 years, we determine the average of the last three determinations of creatinine (modified Jaffe method) and the quotient albuminuria/creatininuria by nephelmometry in the first urine sample. Major CVEs were documented. A history of myocardial infarction, angina pectoris, angioplasty and/or myocardial and/or lower limb revascularization surgery, and cerebrovascular accident were determined as cardiovascular atherosclerotic disease. And non-atherosclerotic cardiovascular disease the history of heart failure and arrhythmias.
Results: 31,5% of the patients had some CVE. In the univariate analysis was registered a significant association between the creatinine values and CVE in the ROC curve, with a cut off value of 1,42 mg/dl (AUC:0,595; p<0,001). A cut off value of albuminuria/creatininuria more than 88 mg/g was associated with more numbers of CVE although the ROC curve was not significant.
Conclusions: in the multivariate analysis by logistic regression, adjusting other variables, the creatinine level,age and cholesterol HDL levels were significantly associated with CVE (178% increased risk for creatinine levels equal or over 1,42 mg/dl) while the albuminuric levels were non significantly associated with CVE.
References
I. Pérez-Loredo J, Lavorato C, Negri A. Tasa de filtración glomerular medida y estimada: numerosos métodos de medición (parte I). Rev Nefrol Dial Traspl 2015;35(3):153-164.
II. Benusan T. Detección de la enfermedad renal por diabetes. Rev Soc Arg Diab 2017;51(3):72-75.
III. Inker L, Eneyana N, Coresh J, Tighiouart H, Wang D, Sang Y, Crews D, Doria A, Estrella M, Froissart M, Grams M, Greene T, et al; Chronic Kidney Disease Epidemiology Collaboration. New creatinine and cystatin C based equations to estimate GFR without race. N Engl J Med 2021;385:1737-1749. doi: 10.1056/NEJMoa2102953.
IV. Kidney disease. Improving global outcomes (KDIGO) CKD work group. KDIGO 2012: clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int 2013;3(Suppl1):1-150.
V. Toyama T, Furuichi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, Kaneko S. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all cause mortality and renal events in diabetic patients:metaanalisis. Plos One 2013;8(8):e71810.
VI. Gerstein H, Mann J, Yi Q, Zinmman B, Dinneen S, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf M; HOPE study investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. JAMA 2001;286:421-426.
VII. Levey A, Grams M, Inker L. Uses of GFR and albuminuria levels in acute and chronic kidney disease. N Engl J Med 2022;386:2120-8.
VIII. Sud M, Tangri N, Pintilie M, Levey AS, Naimark D. Risk of end stage kidney disease and death after cardiovascular events in chronic kidney disease. Circulation 2014;130:458-65.
IX. Sud M, Tangri N, Pintile M, Levey AS, Naimark D. ESDR and death after heart failure in CKD. J Am Soc Nephrol 2015;26:715-22.
X. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32 (suppl 2):64-78
XI. Porrini E, Ruggenenti P, Mogensen CE, Barlovic D, Praga M, Cruzado J, Hojs R, Abbate M, de Vries; ERA-EDTA Diabesity Working Group. Non proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol 2015;3:382-391
XII. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the abscence of albuminuria and retinopathy among adults with type 2 diabetes. JAMA 2003;289:3273-3277
XIII. Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL, Kshirsagar AV. Normoalbuminuric diabetic kidney disease in the U.S population. J Diabetic Complications 2013;27:123-27
XIV. Thomas MC, Mac Isaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC. Non albuminuric renal impairment in type 2 diabetes and in the general population (National Evaluation of the frequency of renal impairment coexisting with NIDDM) NEFRON study. Diabetes Care 2009;32:1497-502.
XV. Alghahi H, Cederholm J, Eliasion B, Zethelius B, Gudbjomsdottir S, Hadimeri H, Svenson MK. Risk factor for the development of albuminuria and renal impairment in type 2 diabetes. The Swedish National Register Neprhol. Dial Transplant 2011;26:1236-43.
XVI. Keith D, Nichols G, Gullon Ch, Brown B, Smith D. Longitudinal follow up and outcomes among patients with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164(6):659-663.
XVII. Birkeland K, Bodegard J, Eriksson J, Norhammar N, Haller H, Linssen G, Bannerjee A, et al. Heart failure and chronic kidney disease manifestation and mortality risk association with type 2 diabetics: a large multinational cohort study. Diab Obs Metab 2020;22(9):1607-1618.
XVIII. Dieuzeide G, Waitman J, Pugnaloni-Rodríguez Rodríguez MV, Nardone L, Oviedo; en representación del grupo de Estudio CAPTURE Argentina. Estudio CAPTURE: resultados argentinos sobre prevalencia de enfermedad cardiovascular en diabéticos tipo 2. Medicina (Bs As) 2022;82:398-407.
XIX. Russo G, Alguwaihes A, Bayram F, Darmon P, Davis T, Eriksen K, Hong T, Kaltof M, Lengyel C, Arenas Leon JL, Mosenzon O, Rhee N, Shirabe S, Urbancova K, Vencio S, Dieuzeide G; for the CAPTURE international investigation group. Prevalence of cardiovascular disease and medication use by CKD risk groups in people with type 2 diabetes: a post hoc analysis from CAPTURE. Oral presentation in the 2020 annual meeting of the American Society of Nephrology Philadelpia. Journal of the American Society of Nephrology Abstrac 2020;(supp).
XX. Reinakaran R, Cull CA, Thorne KI ,Adler AI, Holman RR. Risk factor for renal dysfunction in type 2 diabetes: UK prospective diabetes study 74. Diabetes 2006;55(6): 1832-1839.
XXI. Afkarian M, Sachs M, Kestenbaum B, Hirsch I, Tuttle K, Himmelbarb J, de Boer I. Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 2013;24(2):302-308.
XXII. Toyama T, Furuchi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, Kanejo S, Wada T. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all cause mortality and renal events in diabetic patients: metaanalysis. Plos One 2013;8(8):e71810.
XXIII. Vistisen D, Andersen G, Hulman A, Persson F, Rossin P, Jorgensen M. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria. Diabetes Care 2019;42:1886-1894.
XXIV. Navaneethan D, Zoungas S, Caramori L, Chan L, Heerspink H L, et al.; KDIGO 2022. Clinical practice guidelines for diabetes management in chronic kidney disease. Kidney International 2022;102:55.
XXV. Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Scardapane M, Nicolucci A, Pugliese A; for the Renal Inssuficiency and Cardiovascular Events (RIACE) study group. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicentre study. Diabetol 2018;61:2277-2289.
XXVI. Buyadaa O, Magliano D, Salim A, Koye D, Shaw J. Risk of rapid kidney function decline, all causse mortality and mayor cardiovascular events in nonalbuminuric chronic kidney disease in type 2 diabetes. Diabetes Care 2020;43:122-129.
XXVII. Yokoyama H, Araki S, Kawai K, Yamazaki K, Shirabe S, Sugimoto H, Minami M, Miyazawa I, Maegawa H; for the JDDM study group. The prognosis of patients with type 2 diabetes and normoalbuminuric diabetic kidney disease is not always poor: implications of the effects of coexisting macrovascular complications (JDDM4). Diabetes Care 2020;43:1102-1110.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Copyright 2024 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
